📣 VC round data is live. Check it out!
- Public Comps
- Nanobiotix
Nanobiotix Valuation Multiples
Discover revenue and EBITDA valuation multiples for Nanobiotix and similar public comparables like Recursion Pharmaceuticals, Eris Lifesciences, Pharma Mar, HUTCHMED (China) and more.
Nanobiotix Overview
About Nanobiotix
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Founded
2003
HQ

Employees
108
Website
Financials (LTM)
EV
$2B
Valuation Multiples
Start free trialNanobiotix Financials
Nanobiotix reported last 12-month revenue of $39M and negative EBITDA of ($11M).
In the same LTM period, Nanobiotix generated $39M in gross profit, ($11M) in EBITDA losses, and had net loss of ($21M).
Revenue (LTM)
Nanobiotix P&L
In the most recent fiscal year, Nanobiotix reported revenue of $38M and EBITDA of ($14M).
Nanobiotix is unprofitable as of last fiscal year, with EBITDA margin of (37%) and net margin of (74%).
Financial data powered by Morningstar, Inc.
Nanobiotix Stock Performance
Nanobiotix has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Nanobiotix's stock price is $39.65.
Nanobiotix share price decreased by 0.1% in the last 30 days, and increased by 733.0% in the last year.
Nanobiotix has an EPS (earnings per share) of $-0.55.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -0.1% | -0.1% | 29.9% | 733.0% | $-0.55 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNanobiotix Valuation Multiples
Nanobiotix trades at 53.0x EV/Revenue multiple, and (192.2x) EV/EBITDA.
EV / Revenue (LTM)
Nanobiotix Financial Valuation Multiples
As of June 2, 2026, Nanobiotix has market cap of $2B and EV of $2B.
Nanobiotix has a P/E ratio of (95.6x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nanobiotix Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Nanobiotix Margins & Growth Rates
Nanobiotix grew revenue by 6% but EBITDA decreased by 59% in the last fiscal year.
In the most recent fiscal year, Nanobiotix reported EBITDA margin of (37%) and net margin of (74%).
Nanobiotix Margins
Nanobiotix Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Nanobiotix Operational KPIs
Nanobiotix's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.
Nanobiotix's Rule of 40 is 3% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nanobiotix's Rule of X is 28% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Nanobiotix Competitors
Nanobiotix competitors include Recursion Pharmaceuticals, Eris Lifesciences, Pharma Mar, HUTCHMED (China), Bausch Health, Granules India, Pharvaris, Trevi Therapeutics, Nanjing King-Friend and Aurinia Pharmaceuticals.
Most Nanobiotix public comparables operate across Biopharmaceuticals, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 19.3x | 20.8x | (2.6x) | (2.6x) | |||
| 6.9x | 6.8x | 19.3x | 18.8x | |||
| 7.2x | 7.1x | 22.8x | 22.9x | |||
| 1.4x | 1.3x | 1.5x | (75.7x) | |||
| 2.1x | 2.1x | 6.1x | 5.9x | |||
| 3.7x | 3.6x | 16.6x | 16.2x | |||
| - | - | (9.4x) | (8.9x) | |||
| - | - | (42.4x) | (30.3x) | |||
This data is available for Pro users. Sign up to see all Nanobiotix competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nanobiotix
| When was Nanobiotix founded? | Nanobiotix was founded in 2003. |
| Where is Nanobiotix headquartered? | Nanobiotix is headquartered in France. |
| How many employees does Nanobiotix have? | As of today, Nanobiotix has over 108 employees. |
| Who is the CEO of Nanobiotix? | Nanobiotix's CEO is Laurent Levy. |
| Is Nanobiotix publicly listed? | Yes, Nanobiotix is a public company listed on Euronext Paris. |
| What is the stock symbol of Nanobiotix? | Nanobiotix trades under NANO ticker. |
| When did Nanobiotix go public? | Nanobiotix went public in 2012. |
| Who are competitors of Nanobiotix? | Nanobiotix main competitors include Recursion Pharmaceuticals, Eris Lifesciences, Pharma Mar, HUTCHMED (China), Bausch Health, Granules India, Pharvaris, Trevi Therapeutics, Nanjing King-Friend, Aurinia Pharmaceuticals. |
| What is the current market cap of Nanobiotix? | Nanobiotix's current market cap is $2B. |
| What is the current revenue of Nanobiotix? | Nanobiotix's last 12 months revenue is $39M. |
| What is the current revenue growth of Nanobiotix? | Nanobiotix revenue growth (NTM/LTM) is 33%. |
| What is the current EV/Revenue multiple of Nanobiotix? | Current revenue multiple of Nanobiotix is 53.0x. |
| Is Nanobiotix profitable? | No, Nanobiotix is not profitable. |
| What is the current EBITDA of Nanobiotix? | Nanobiotix has negative EBITDA and is not profitable. |
| What is Nanobiotix's EBITDA margin? | Nanobiotix's last 12 months EBITDA margin is (28%). |
| What is the current EV/EBITDA multiple of Nanobiotix? | Current EBITDA multiple of Nanobiotix is (192.2x). |
| What is the current FCF of Nanobiotix? | Nanobiotix's last 12 months FCF is ($36M). |
| What is Nanobiotix's FCF margin? | Nanobiotix's last 12 months FCF margin is (92%). |
| What is the current EV/FCF multiple of Nanobiotix? | Current FCF multiple of Nanobiotix is (57.3x). |
| How many companies Nanobiotix has acquired to date? | Nanobiotix hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Nanobiotix has invested to date? | Nanobiotix hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Nanobiotix
Lists including Nanobiotix
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.